RxDoctor Payments Data

Jared Cook, MD

Nephrology · Birmingham, ALNPI 1598177719

Payments from drug & device makers

What this record shows

This record is dominated by grants: $24,878 of the $25,381 with a category attached, or 98.0%. Sanofi accounts for 98.0% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2019 at $25,202 and has fallen 100.0% since, to $6 in 2025.

$25,381in general payments, 2019–2025

Across 13 payments — averaging $1952.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$25K
  • AstraZeneca$209
  • Amgen$116
  • Fresenius USA Marketing, Inc.$52
  • Baxter Healthcare$39
  • Otsuka America Pharmaceutical, Inc.$39
  • plus $48 from 3 others

What the payments were for

  • Grants$24,87898%
  • Food & beverage$4082%
  • Education$950%

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$25,381 in reported general payments places this provider in the 85th percentile of 164 nephrology providers in Alabama.

See all nephrology providers in Alabama

Medicare billing

Part B allowed, 2024
$98,344
Medicare patients
252
Services billed
933

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol47$37,988
LokelmaSodium Zirconium Cyclosilicate27$23,410
VeltassaPatiromer Calcium Sorbitex14$13,443
Sevelamer Carbonate16$3,075
Chlorthalidone68$1,210
Losartan Potassium87$1,121
Amlodipine Besylate85$456
Olmesartan Medoxomil15$407
Carvedilol38$349
Lisinopril38$347
Tamsulosin Hcl12$316
Calcitriol21$292
Atorvastatin Calcium20$281
Nifedipine ErNifedipine16$254
Spironolactone22$212

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$209$61,39874 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 164 nephrology providers in Alabama.

Other nephrology in Birmingham

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →